Generic Voxzogo Availability
Last updated on Apr 10, 2025.
Voxzogo is a brand name of vosoritide, approved by the FDA in the following formulation(s):
VOXZOGO (vosoritide - powder;subcutaneous)
-
Manufacturer: BIOMARIN PHARM
Approval date: November 19, 2021
Strength(s): 0.4MG/VIAL [RLD], 0.56MG/VIAL [RLD], 1.2MG/VIAL [RLD]
Is there a generic version of Voxzogo available?
No. There is currently no therapeutically equivalent version of Voxzogo available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Voxzogo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
Patent 10,646,550
Issued: May 12, 2020
Inventor(s): Bullens Sherry & Bunting Stuart & Chou Tianwei & Okhamafe Augustus O. & Price Christopher P. & Wendt Daniel J. & Yap Clarence
Assignee(s): BioMarin Pharmaceutical Inc.The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
Patent expiration dates:
- August 1, 2036✓✓
- August 1, 2036
-
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
Patent 11,590,204
Issued: February 28, 2023
Inventor(s): Bullens; Sherry et al.
Assignee(s): BIOMARIN PHARMACEUTICAL INC. (Novato, CA)The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
Patent expiration dates:
- August 1, 2036✓✓
- August 1, 2036
-
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
Patent 11,911,446
Issued: February 27, 2024
Inventor(s): Bullens; Sherry et al.
Assignee(s): BIOMARIN PHARMACEUTICAL INC. (Novato, CA)The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
Patent expiration dates:
- August 1, 2036✓
- August 1, 2036
-
C-type natriuretic peptide variants to treat skeletal dysplasia in children
Patent 12,233,106
Issued: February 25, 2025
Inventor(s): Day; Jonathan et al.
Assignee(s): BIOMARIN PHARMACEUTICAL INC. (Novato, CA)treatment of skeletal dysplasias in children, and improvement in one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, by administering variants of C-type natriuretic peptide (CNP) is described.
Patent expiration dates:
- July 11, 2042✓
- July 11, 2042
-
Variants of C-type natriuretic peptide
Patent 8,198,242
Issued: June 12, 2012
Inventor(s): Wendt Daniel J. & Long Shinong & Castillo Sianna & Price Christopher P. & Aoyagi-Scharber Mika & Vellard Michel C. & Okhamafe Augustus O.
Assignee(s): Biomarin Pharmaceutical Inc.The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
Patent expiration dates:
- June 11, 2030✓✓✓
- June 11, 2030
-
Use of C-type natriuretic peptide variants to treat skeletal dysplasia
Patent 9,907,834
Issued: March 6, 2018
Inventor(s): Bullens Sherry & Bunting Stuart & Chou Tianwei & Okhamafe Augustus O. & Price Christopher P. & Wendt Daniel J. & Yap Clarence
Assignee(s): BioMarin Pharmaceutical Inc.The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
Patent expiration dates:
- August 1, 2036✓
- August 1, 2036
-
Variants of C-type natriuretic peptide
Patent RE48267
Issued: October 20, 2020
Inventor(s): Wendt Daniel J. & Long Shinong & Castillo Sianna & Price Christopher P. & Aoyagi-Scharber Mika & Vellard Michel Claude & Okhamafe Augustus O.
Assignee(s): BioMarin Pharmaceutical Inc.The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
Patent expiration dates:
- May 20, 2030✓
- May 20, 2030
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- October 20, 2026 - NEW PATIENT POPULATION
- November 19, 2026 - NEW CHEMICAL ENTITY
- November 19, 2028 - TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES
- October 20, 2030 - TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS LESS THAN 5 YEARS OF AGE WITH ACHONDROPLASIA WITH OPEN EPIPHYSES
More about Voxzogo (vosoritide)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous hormones
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
